Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Ross

Showing results (461-470 of 587) with videos related to

Pageof 59
Sort By:
Annals of Surgical Oncology|February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 TrialCharles H Yoon, Merrick I Ross, Brian R Gastman, et al.
Annals of Surgical Oncology|March 16, 2026
Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal DissectionJoshua Herb, Roland L Bassett, Carlos A Torres-Cabala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2020
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanomaM T Tetzlaff, C Adhikari, S Lo, et al.
Annals of Surgical Oncology|February 18, 2014
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patientsCharles M Balch, John F Thompson, Jeffrey E Gershenwald, et al.
British Journal of Cancer|August 30, 2008
Phase II trial of imatinib mesylate in patients with metastatic melanomaK B Kim, O Eton, D W Davis, et al.
European Journal of Cancer (Oxford, England : 1990)|October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyMuhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Annals of Surgical Oncology|October 14, 2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III MelanomaElan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaM T Tetzlaff, J L Messina, J E Stein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
Melanoma, version 2.2013: featured updates to the NCCN guidelinesDaniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
Annals of Surgical Oncology|June 8, 2011
Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter databaseRichard L White, Gregory D Ayers, Virginia H Stell, et al.
Pageof 59

Showing results (461-470 of 587) with videos related to

Sort By:
Pageof 59
Annals of Surgical Oncology|February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 TrialCharles H Yoon, Merrick I Ross, Brian R Gastman, et al.
Annals of Surgical Oncology|March 16, 2026
Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal DissectionJoshua Herb, Roland L Bassett, Carlos A Torres-Cabala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 3, 2020
Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanomaM T Tetzlaff, C Adhikari, S Lo, et al.
Annals of Surgical Oncology|February 18, 2014
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patientsCharles M Balch, John F Thompson, Jeffrey E Gershenwald, et al.
British Journal of Cancer|August 30, 2008
Phase II trial of imatinib mesylate in patients with metastatic melanomaK B Kim, O Eton, D W Davis, et al.
European Journal of Cancer (Oxford, England : 1990)|October 6, 2022
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 studyMuhammad A Khattak, Jason J Luke, Georgina V Long, et al.
Annals of Surgical Oncology|October 14, 2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III MelanomaElan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2018
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaM T Tetzlaff, J L Messina, J E Stein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
Melanoma, version 2.2013: featured updates to the NCCN guidelinesDaniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
Annals of Surgical Oncology|June 8, 2011
Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter databaseRichard L White, Gregory D Ayers, Virginia H Stell, et al.
Pageof 59